A biotechnology startup, Life Biosciences, has initiated a clinical trial treating the first human with a cellular reprogramming therapy aimed at reversing aging. This therapy, which utilizes three Yamanaka factors to restore youthful cellular states, is being tested on optic nerve cells to assess its safety and potential for regeneration. While the primary focus is safety, this trial represents a significant step in evaluating cellular rejuvenation in humans. AI
RANK_REASON The cluster describes a clinical trial for a novel therapy, which falls under research. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →